The purpose of this study is to determine how safe and effective fondaparinux is in treating
patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).
Currently, standard treatment of HIT involves the transition from a direct thrombin
inhibitor (a type of anticoagulant or "blood thinner") to warfarin, a different type of
anticoagulant. Direct thrombin inhibitors (DTIs) require IV administration and frequent
blood draws for dose adjustments, which can lead to prolonged hospitalization. DTIs also
affect blood test measurements, making it difficult to determine proper dosages of warfarin.
Fondaparinux is a drug that is approved by the FDA for the treatment of blood clots in deep
veins and in the lungs. Fondaparinux is not FDA approved for the treatment of HIT.
However, an increasing number of doctors are using fondaparinux instead of DTIs to treat
HIT. Although fondaparinux appears to be more convenient and predictable than DTI
medications, more research is needed to support its use as a treatment for HIT.
- high risk for HIT based on "Four Ts score" of 6 or more
- pulmonary emboli at the time of enrollment
- arterial thrombosis at the time of enrollment
- limb threatening phlegmasia cerulea dolens at the time of enrollment
- Calculated Creatinin Clearance less than 50 ml/hr
- platelet count less than 50
- Weight less than 50 kg
- allergy to fondaparinux
- bacterial endocarditis
- history of neuraxial anesthesia and post-operative indwelling epidural catheter
- active major bleeding (hemodynamically significant or requiring transfusions)
- inability to give informed consent